Introduction {#sec1}
============

Chronic pain is among the most frequent complaints encountered by physicians. The International Association for the Study of Pain (IASP) estimated that chronic pain, including musculoskeletal afflicts about 20% (10--55%) of the adult population worldwide \[[@cit0001]\]. Fibromyalgia syndrome (FMS) is a common form of chronic pain and affecting approximately 2--4% of the adult female population \[[@cit0002]\].

FMS is characterized by widespread pain, tenderness and diffuse stiffness. Other associated symptoms include mood, cognitive and functional impairments, such as fatigue, sleep disturbances and headaches \[[@cit0003], [@cit0004]\]. Research indicate that familial, genetic, environmental, endocrine and neurological factors play a role in the emergence of this disorder \[[@cit0002], [@cit0005]--[@cit0007]\].

Several studies have described comorbidities related to FMS \[[@cit0005]\]. The current report evaluated the association of FMS with diabetes mellitus (DM) using the clinical database of Clalit Health Services (CHS), the largest Health Maintenance Organization (HMO) in Israel. CHS serves a population of about 4,400,000 enrollees. The CHS database allows evaluating "real-life" populations on a large scale, including outpatients and inpatients in primary, secondary and tertiary care centers.

Material and methods {#sec2}
====================

We conducted a cross-sectional, population-based study using data from CHS. The HMO has a comprehensive, electronic database with continuous, real-time input from pharmaceutical, medical and administrative systems.

In the CHS database, the diagnoses of chronic diseases are based on data derived from hospital and community-based physicians' records. These diagnoses are validated systematically using logistic checks (such as comparing diagnoses from various providers). The validity of the diagnoses in the registry has been shown to be high \[[@cit0008]--[@cit0010]\].

Patients were defined as having FMS or DM when their medical record contained at least one diagnosis by a physician. All FMS patients in the CHS database were included in our study.

It should be mentioned that in this study more than half of the diagnoses were coded by family physicians (taken from encounters of primary, secondary and tertiary care and often derived from private practice care as well). Thus, a diagnosis coded by family physicians doesn't necessarily mean that a specialist did not perform the actual diagnosis but rather he was not the one to code it into the system.

The control group was randomly selected from CHS enrollees, five control subjects never diagnosed with FMS, who were matched to each FMS patient by gender and age. Data from the CHS database included age, sex, body mass index (BMI), socioeconomic status (SES), smoking status, and diagnoses of chronic diseases, including oncologic disorders.

The distribution of sociodemographic and clinical factors was compared between patients with and without FMS using χ^2^ test for categorical variables and student's t-test for continuous variables. Crude odds ratios (OR), as well as 95% confidence intervals (CI) are presented.

The study was approved by the CHS Ethics Committee, located at Soroka Medical Center, Beer Sheva, Israel.

Results {#sec3}
=======

The study included 14,296 FMS patients and 71,324 age- and sex-matched controls. FMS patients and controls were at about a mean age of 55 years, and 92.4% were women ([Table I](#t0001){ref-type="table"}). FMS patients were more likely to be at a low or medium SES and more likely to be smokers than controls were. Their BMI was higher compared to controls (29.1 vs. 28.0 kg/m^2^, respectively; *p* \< 0.001) ([Table I](#t0001){ref-type="table"}).

###### 

Descriptive characteristics of the study population (*n* = 85,620)

  Characteristic   Fibromyalgia *n* = 14,296   No fibromyalgia *n* = 71,324   Odds ratio (CI)     *p*-value
  ---------------- --------------------------- ------------------------------ ------------------- -----------
  Age              55.2 ±13.9                  56.0 ±13.7                     1.00 (0.99--1.00)   \< 0.001
  Females          13210 (92.4%)               65910 (92.4%)                  1.00 (0.93--1.07)   0.978
  BMI              29.1 ±6.20                  28.0 ±6.01                     1.03 (1.03--1.03)   \< 0.001
  Smoking          4679 (32.7%)                19987 (28.0%)                  1.25 (1.20--1.30)   0
  SES                                                                                             
   Low             6669 (46.8%)                27747 (39.2%)                  Ref.                Ref.
   Medium          5397 (37.9%)                27499 (38.8%)                  0.82 (0.78--0.85)   0
   High            2182 (15.3%)                15554 (22.0%)                  0.58 (0.55--0.61)   0
   Diabetes        12391 (17.4%)               2832 (19.8%)                   1.17 (1.12--1.23)   \< 0.001

BMI -- body mass index (kg/m^2^); SES -- socioeconomic status

In the control group 12,391 patients (17.4%) were found to have concomitant DM compared to 2,832 (19.8%) of the FMS patients. DM was significantly higher in FMS patients with an odds ratio for having concomitant DM at 1.17 (95% CI: 1.12--1.23, *p* \< 0.001).

Discussion {#sec4}
==========

This population-based, cross-sectional study was designed to investigate the association between FMS and DM, in a sex- and age-matched analysis.

According to the WHO, in 2014, 422 million people in the world had diabetes -- a prevalence of 8.5% among the adult population. The prevalence of diabetes has been increasing over the past 30 years as well as the associated risk factors such as being overweight or obese \[[@cit0011]\].

A publication by the Israel Center for Disease Control (ICDC) estimates that DM is today is the fourth leading cause of death in Israel. In 2013, 5% of deaths in men and 5.9% in women were attributed to diabetes and its' complications. According to the Israeli National Health Survey (INHIS-3) DM type 2 affects 8.8% of men and 8.1% of women over the age of 21 years escalating to rates of 27.3% in men and 20.5% in women older than 65 \[[@cit0012]\]. Beyond the age of 55 the rates in men exceeds those reported in women.

DM is associated with many complications that eventually result in high rates of morbidity and mortality including hypoglycemia episodes, diabetic coma, neuropathy, nephropathy, hypertension, stroke, hyperosmolar hyperglycemic nonketotic syndrome, diabetic ketoacidosis and ketones, amputation, gastroparesis, microangiopathy, macrovascular disease and many others \[[@cit0011]\]. It is highly likely that some of the complications mentioned above may cause symptoms of pain, mood and sleeping disturbances.

Most of the literature to date shows higher rates of FMS in patients with DM ranging from 17% to 23.3% \[[@cit0013]--[@cit0016]\]. Results from our study correspond with the literature as DM was found in a proportion of 19.4% of patients with FMS with an OR of 1.17 compared to controls.

Results from Tishler et al. \[[@cit0014]\] on 100 consecutive, unselected DM patients (45 DM type 1 and 55 DM type 2) and 50 randomly recruited healthy hospital staff as controls, revealed an association of FMS with elevated HbA~1c~ levels as well as a correlation between HbA~1c~ levels and the number of tender points. DM patients with FMS have more tender points and more complaints of widespread pain compared with controls \[[@cit0013], [@cit0017], [@cit0018]\]. Italian researchers even suggested that insulin resistance might be a risk factor for memory deficit among patients with FMS through sympathetic nervous system activation and hypothalamic pituitary axis dysregulation \[[@cit0019]\].

FMS and diabetic peripheral neuropathy share many aspects. A study of 100 patients with type 2 DM patients showed that peripheral neuropathy was detected in 61.9% of patients with DM and FMS compared to only 2.5% in patients with DM without FMS \[[@cit0015]\].

The main limitation of this study was the fact that we relied on diagnoses appearing in the patients' medical records. By nature, we had no confirmation of their validity according to the classification criteria applied in clinical studies. The CHS database was originally created to accommodate data for clinical proposes, therefore, it was designed to act as a data registry according to diagnostic criteria of disorders but rather to code diseases according to the International Classification of Diseases (ICD) for statistical, economical and administrative purposes. However, the validity of the diagnoses as exhibited in previous studies have been shown to be high and reliable \[[@cit0008], [@cit0009], [@cit0020]--[@cit0024]\].

The main strength of this study is its large sample size. The CHS database that we used in this study covers more than half of the population in Israel. Thus the data represent the entire general population composed by the matrix of the diverse ethnicities, socioeconomic backgrounds and geographical differences.

Conclusions {#sec5}
===========

In conclusion, both DM and FMS are common in the general population. Our study indicates that FMS patients seem to be prone to have concomitant DM regardless of which condition was discovered first. Consequently, physicians treating DM patients should be aware of the symptomatology of FMS, it's association with obesity and refer selected patients to a rheumatologist to properly diagnose and treat FMS.
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